Urate-lowering therapy for patients with gout on hemodialysis
- PMID: 35570645
- PMCID: PMC9542196
- DOI: 10.1111/1756-185X.14334
Urate-lowering therapy for patients with gout on hemodialysis
Abstract
Objective: Gout is the most common form of inflammatory arthritis and is caused by deposition of monosodium urate crystals resulting from a high burden of uric acid (UA). High UA burden also has been associated with increased morbidity and mortality in the general population and progression to chronic kidney disease. In persons with gout and end-stage renal disease (ESRD), prior studies suggest that UA levels decrease after initiation of hemodialysis (HD). We evaluated UA level and the use of urate-lowering therapies (ULTs) in patients with gout and ESRD on HD.
Methods: We performed a retrospective review of patients with gout and ESRD seen at a large urban public hospital (The MetroHealth System). We extracted data from the medical record (Epic) for patients diagnosed with gout and ESRD on HD. The main outcomes were the UA level and the use of ULTs before and after HD initiation.
Results: We identified 131 patients with gout on HD. Of these, 21 patients had crystal proven gout diagnosis, 10 of whom had data on UA level pre-HD and post-HD and were included in the analysis. For the total sample (N = 21), the mean age was 65 years, 7 were female and 20 were African American. Mean pre-HD and post-HD UA levels were 8.4 and 3.98 mg/dL respectively. Twenty-one patients were receiving ULT pre-HD, 11 discontinued post-HD.
Conclusion: Among patients with gout and ESRD, we observed a decrease in UA level associated with initiation of HD. For this group, discontinuation of ULTs may be appropriate.
Keywords: end-stage renal disease on hemodialysis; gout arthritis; urate-lowering therapy.
© 2022 The Authors. International Journal of Rheumatic Diseases published by Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.
Conflict of interest statement
No conflict of interest.
Figures
Comment in
-
Letter to the editor regarding "urate-lowering therapy for patients with gout on hemodialysis".Int J Rheum Dis. 2023 Jan;26(1):177-178. doi: 10.1111/1756-185X.14469. Epub 2022 Oct 17. Int J Rheum Dis. 2023. PMID: 36250780 No abstract available.
-
Response to "Urate lowering therapy for patients with gout on hemodialysis".Int J Rheum Dis. 2023 Mar;26(3):585. doi: 10.1111/1756-185X.14527. Epub 2022 Dec 20. Int J Rheum Dis. 2023. PMID: 36537622 No abstract available.
Similar articles
-
Target Serum Urate Achievement and Chronic Kidney Disease Progression in Patients With Gout and Kidney Disease.JAMA Intern Med. 2025 Jan 1;185(1):74-82. doi: 10.1001/jamainternmed.2024.6212. JAMA Intern Med. 2025. PMID: 39585678 Free PMC article.
-
Dyslipidemia, Alcohol Consumption, and Obesity as Main Factors Associated With Poor Control of Urate Levels in Patients Receiving Urate-Lowering Therapy.Arthritis Care Res (Hoboken). 2018 Jun;70(6):918-924. doi: 10.1002/acr.23347. Epub 2018 Mar 23. Arthritis Care Res (Hoboken). 2018. PMID: 28834411
-
Serum urate levels and therapy in adults treated with long-term dialysis: a retrospective cross-sectional study.Intern Med J. 2019 Jul;49(7):838-842. doi: 10.1111/imj.14163. Intern Med J. 2019. PMID: 30426652
-
Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia.Clin Exp Nephrol. 2020 Mar;24(Suppl 1):1-5. doi: 10.1007/s10157-019-01811-9. Epub 2019 Nov 21. Clin Exp Nephrol. 2020. PMID: 31754883 Free PMC article. Review.
-
Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review.J Gen Intern Med. 2018 Mar;33(3):358-366. doi: 10.1007/s11606-017-4233-5. Epub 2017 Dec 4. J Gen Intern Med. 2018. PMID: 29204974 Free PMC article.
Cited by
-
Use of Epic Electronic Health Record System for Health Care Research: Scoping Review.J Med Internet Res. 2023 Dec 15;25:e51003. doi: 10.2196/51003. J Med Internet Res. 2023. PMID: 38100185 Free PMC article.
-
Dosing practices, pharmacokinetics, and effectiveness of allopurinol in gout patients receiving dialysis: a scoping review.J Nephrol. 2025 Apr;38(3):859-875. doi: 10.1007/s40620-025-02269-7. Epub 2025 Mar 25. J Nephrol. 2025. PMID: 40131716 Free PMC article.
-
Risk factors and management of hyperuricemia after renal transplantation.Front Surg. 2023 Jan 6;9:956213. doi: 10.3389/fsurg.2022.956213. eCollection 2022. Front Surg. 2023. PMID: 36760666 Free PMC article. Review.
References
-
- Dousdampanis P, Trigka K, Musso CG, et al. Hyperuricemia and chronic kidney disease: an enigma yet to be solved. Ren Fail. 2014;36(9):1351‐1359. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical